News Detail
New Delhi, 14 July 2022: A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional......
View Details
Source : India TV
Related News
- IIT-BHU developing med device with potential to cure sclerosis (28-11-2024)
- Three widely used BP medicines Combo, five times more effective than current drugs (19-11-2024)
- More than half of patients with rheumatic, musculoskeletal disease use OTC supplements: Study (18-11-2024)
- One-third of older people and individuals admitted to the hospital experienced ADRs: Study (17-11-2024)
- Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII–biointerface binding (13-11-2024)
- IISc scientists develop enzyme-based solution to break antibiotic-resistant biofilms (13-11-2024)
- Japan performs world's first stem cell-treatment to restore vision (12-11-2024)
- Scientist treated her own cancer with viruses she grew in the lab (12-11-2024)
- Innovative use of silk in medical devices (10-11-2024)
- Three-fold throughput nitrosamine analysis in drug products using SIFT-MS (07-11-2024)